Thromboembolic Disaster after Atrial Ablation: Use of Novel Anticoagulation by Farhoud, Mahmoud et al.
Kansas Journal of Medicine 2015              Thromboembolic Disaster after Atrial Ablation 
30 
 
 
 
 
 
 
 
 
 
 
 
 
 
Thromboembolic Disaster after 
Atrial Ablation:  
Use of Novel Anticoagulation 
Mahmoud Farhoud, M.D.1 
Valerie S. Cagle, M.D.2 
Wassim Shaheen, M.D.3,4 
1University of Central Florida  
College of Medicine, Orlando, FL 
2Tulane University School of Medicine,  
New Orleans, LA 
3Heartland Cardiology, P.A., Wichita, KS 
4University of Kansas  
School of Medicine-Wichita, KS 
 
Introduction
Atrial fibrillation (AF) may result in 
thromboembolism often from a thrombus in 
the left atrium or atrial appendage 
accounting for nearly 15% of all strokes in 
the US,1 with an annual incidence of stroke 
of up to 6% or higher in some patients.2 
Atrial fibrillation ablation, if successful over 
the long-term, may reduce the risk of future 
stroke. New anticoagulants, such as 
dabigatran, rivaroxaban, and apixaban, have 
been shown to be superior to warfarin to 
reduce the risk of stroke in non-valvular 
atrial fibrillation (NVAF), but no solid data 
are available to show if they are appropriate 
to utilize as an alternative to warfarin in 
patients undergoing catheter ablation 
procedures. Our case illustrated that such 
therapy may not be efficient.  
 
Case Report 
A fifty-year-old male underwent catheter 
ablation for symptomatic paroxysmal atrial 
fibrillation. He is known to have 
dyslipidemia, hypertension, and coronary 
artery disease. He was diagnosed with 
paroxysmal NVAF and despite the use of 
several antiarrhythmic mediations, including 
dronedarone and propafenone, normal sinus 
rhythm could not be maintained. Hence, he 
underwent atrial ablation with a pre-
procedural transesophageal echocardiogram 
that did not reveal any intracardiac 
thrombus. Prior to the ablation procedure, he 
had been anticoagulated with warfarin for 
more than four weeks with an international 
normalized ratio (INR) documented above 
two. He was discharged on warfarin and 
sotalol with a one-week follow-up. 
At the follow-up visit, the patient’s post-
ablation anticoagulation regimen was 
changed from warfarin to apixaban per the 
patient’s request not to take warfarin 
anymore. Approximately two weeks later, 
the patient presented to the emergency 
department due to the sudden onset of 
weakness and dizziness. He also had a fever 
of more than 101oF and cough.  
A chest x-ray revealed a left lower lobe 
infiltrate. His electrocardiogram showed 
normal sinus rhythm. Other laboratory 
values were unremarkable except for 
leukocytosis and elevated troponin at 7.91 
ng/ml (normal range less than 0.05 ng/ml).  
A CT scan of the brain showed a small 
subarachnoid hemorrhage in the right upper 
precentral sulcus. A transthoracic echo-
cardiogram showed a 3 cm mobile thrombus 
in the left atrium.  
His initial blood culture results were 
suggestive of gram positive cocci in a 
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streptococcal arrangement. Vancomycin and 
cefepime were started. Later, the final 
culture results were positive for 
streptococcus mitis and oralis.  
A transesophageal echo on the following 
day showed an ejection fraction of 30% and 
a 3.7 cm long mobile thrombus attached to 
the roof of the left atrium (Figure 1). He also 
had recurrent episodes of atrial fibrillation 
during his hospital course.  
 
 
Figure 1. A transesophageal echo showed a 
3.7 cm long mobile thrombus attached to the 
roof of the left atrium (arrow), LA: left atrium, 
LV: left ventricle. 
 
Unfortunately, his neurological status 
deteriorated and he became unresponsive 
with a fixed and dilated left pupil. A repeat 
CT of the brain revealed thromboembolic 
lesion of disastrous proportions, “every area 
of the brain was involved with too many 
new lesions to report” (Figure 2). The CT 
scan also was significant for air bubbles 
over the top of the left parietal lobe. The 
patient was provided comfort care and 
subsequently expired immediately after 
extubation.  
 
Discussion 
Several complications are associated 
with catheter ablation in the left atrium.  Our 
patient developed a post-procedure throm-
bus in the left atrium which we strongly feel 
became infected with secondary septic 
thromboembolism. This likely caused a 
mycotic aneurysm and hence the initial
 
 
Figure 2. A CT of the head revealed multiple 
thromboembolic lesions (arrows). 
 
small subarachnoid hemorrhage was seen on 
the first CT scan of the brain. There also was 
fistula, a known but rare complication of 
ablation. There is also the suggestion of a 
developing atrioesophageal fistula, a known 
but rare complication of ablation. While this 
diagnosis could not be confirmed, as the 
patient was unstable to have any additional 
tests, the blood cultures showing 
streptococcus viridans and the air seen over 
the left parietal lobe on the final CT scan 
strongly supported our suspicion.3,4 
NVAF patients are at increased short-
term risk of thromboembolism after their 
ablation.5 Several factors are implicated: the 
trans-septal sheath placement can precipitate 
thrombus formation on the catheter or sheath 
during the procedure or in the left atrial 
appendage,6,7 delivery of radiofrequency 
energy during the ablation disrupts the 
endocardium activating the clotting 
cascade,8 “char” (hard coagulum) from 
tissue heating and denaturation and 
aggregation of plasma proteins9 may form 
and systemically embolize,6 and  the atrial 
tissue may be stunned post-procedure 
leading to impairment of normal 
contraction.10 
To minimize this risk, anticoagulation is 
initiated as part of the ablation procedure. 
Current practice involves pre-ablation 
anticoagulation with warfarin, then anti-
coagulation with heparin during the 
procedure without discontinuation of 
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warfarin, followed by post-procedural 
anticoagulation, usually with warfarin for 
three to six months.11,12 
 Our patient, anticoagulated with 
apixaban, developed a thrombus nearly four 
centimeters in length on the roof of the left 
atrium that resulted in fatal neurologic 
complications. Apixaban is an oral direct 
factor Xa inhibitor. The initial studies for 
apixaban have been promising, both in the 
context of NVAF as well as anticoagulation 
for cardioversion, with none of the over 300 
patients on apixaban undergoing cardio-
version in the ARISTOTLE trial having 
stroke over the next 30 days.13 
Winkle et al.14 demonstrated dabigatran 
as safe and well tolerated after AF ablation. 
On the other hand, a larger multicenter 
study15 reported that peri-procedural 
dabigatran use significantly increases the 
risk of complications compared with 
uninterrupted warfarin therapy. Due to the 
novelty of the oral anticoagulants, the 
studies are limited and there are likely many 
factors in the equation not yet recognized or 
explored. Our case is the first reported case 
that shows using apixaban following 
ablation may not be appropriate. 
 
Conclusion 
Despite the recent studies that showed 
apixaban to be a safe and effective 
anticoagulant in the prevention of stroke in a 
patient with NVAF compared to warfarin, 
physicians should be careful in extrapolating 
these data to a patient undergoing NVAF 
ablation. One can only speculate on how the 
use of apixaban, instead of warfarin, 
affected our patient’s outcome. Our case 
illustrated the need for caution and further 
studies on the use of the new factor Xa 
inhibitors in such patient populations. 
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